Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Additionally, using higher doses of dexamethasone for prolonged periods of time can lead to severe side effects and some patients may develop corticosteroid resistance leading to treatment failure." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "Recent trials with dexamethasone and hydrocortisone have demonstrated benefit in patients with coronavirus disease 2019 (COVID)-19)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "early dexamethasone group showed a significantly lower rate of severe COVID-19 compared to the control group (75.9% vs 40.0%, P-value=0.012)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "high dose corticosteroid pulse therapy (HDCPT) with either methylprednisolone or dexamethasone showed a statistically significant decrease in mortality (HR) = 0.087 [95% CI 0.021-0.36]; P < 0.001)." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "We's investigation into the significance of COX-2-prostaglandin E2 (PGE2) pathway also revealed that DV infection enhances human DC infected by DV migration by inducing CC chemokine receptor 7 (CCR7) expression, and that blocking COX-2 or MAPK activity suppresses DV-induced human DC infected by DV migration." provenance.
- SENTENCE label "Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner." provenance.
- SENTENCE label "Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner." provenance.
- SENTENCE label "Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner." provenance.
- SENTENCE label "Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner." provenance.
- SENTENCE label "Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner." provenance.
- SENTENCE label "Treatment of fibroblasts by dexamethasone increased Aminopeptidase N activity in a dose- and time-dependent manner." provenance.
- SENTENCE label "glycyrrhizin (GL), as well as dexamethasone (DEX) inhibited both tumor necrosis factor (TNF)-α –and IL-1β –induced IL-8 production, mRNA expression, and promoter activity in A549 lung epithelial cells." provenance.
- SENTENCE label "glycyrrhizin (GL), as well as dexamethasone (DEX) inhibited both tumor necrosis factor (TNF)-α –and IL-1β –induced IL-8 production, mRNA expression, and promoter activity in A549 lung epithelial cells." provenance.
- SENTENCE label "To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing." provenance.
- SENTENCE label "To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing." provenance.
- SENTENCE label "To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing." provenance.
- SENTENCE label "To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing." provenance.
- SENTENCE label "To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing." provenance.
- SENTENCE label "To date, only dexamethasone has shown to be an effective treatment in the subgroup of patients requiring oxygen supplementation; however, countless trials including novel therapeutic approaches are ongoing." provenance.
- SENTENCE label "According to the current literature We reviewed, We suggest that IFN-α and arbidol can be retained in the treatment regimen for pregnant women and that to reduce maternal mortality, appropriate doses of dexamethasone can be given to those who are predicted to have low premature survival and to receive mechanical ventilation or oxygen." provenance.
- SENTENCE label "According to the current literature We reviewed, We suggest that IFN-α and arbidol can be retained in the treatment regimen for pregnant women and that to reduce maternal mortality, appropriate doses of dexamethasone can be given to those who are predicted to have low premature survival and to receive mechanical ventilation or oxygen." provenance.
- SENTENCE label "According to the current literature We reviewed, We suggest that IFN-α and arbidol can be retained in the treatment regimen for pregnant women and that to reduce maternal mortality, appropriate doses of dexamethasone can be given to those who are predicted to have low premature survival and to receive mechanical ventilation or oxygen." provenance.